Pathogenesis of COPD.
Chronic obstructive pulmonary disease (COPD) is characterized and defined by limitation of expiratory airflow. This can result from several types of anatomical lesions, including loss of lung elastic recoil and fibrosis and narrowing of small airways. Inflammation, edema, and secretions also contribute variably to airflow limitation. Smoking can cause COPD through several mechanisms. First, smoke is a powerful inducer of an inflammatory response. Inflammatory mediators, including oxidants and proteases, are believed to play a major role in causing lung damage. Smoke can also alter lung repair responses in several ways. Inhibition of repair may lead to tissue destruction that characterizes emphysema, whereas abnormal repair can lead to the peribronchiolar fibrosis that causes airflow limitation in small airways. Genetic factors likely play a major role and probably account for much of the heterogeneity susceptibility to smoke and other factors. Many factors may play a role, but to date, only alpha-1 protease inhibitor deficiency has been unambiguously identified. Exposures other than cigarette smoke can contribute to the development of COPD. Inflammation of the lower respiratory tract that results from asthma or other chronic disorders may also contribute to the development of fixed airway obstruction. COPD is not only a disease of the lungs but is also a systemic inflammatory disorder. Muscular weakness, increased risk for atherosclerotic vascular disease, depression, osteoporosis, and abnormalities in fluids and electrolyte balance may all be consequences of COPD. Advances in understanding the pathogenesis of COPD have the potential for identifying new therapeutic targets that could alter the natural history of this devastating disorder.
Spurzem
John R
JR
Pulmonary and Critical Care Medicine, University of Nebraska Medical Center, 985300 Nebraska Medical Center, Omaha, NE 68198-5300, USA. jspurzem@unmc.edu
Rennard
Stephen I
SI
D000403:Airway Resistance; D017209:Apoptosis / Q000502:physiology; D016207:Cytokines / Q000032:analysis / Q000378:metabolism*; D004785:Environmental Pollutants / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D009093:Mucus / Q000378:metabolism; D011379:Prognosis; D029424:Pulmonary Disease, Chronic Obstructive / Q000209:etiology* / Q000401:mortality / Q000503:physiopathology*; D011656:Pulmonary Emphysema / Q000150:complications / Q000175:diagnosis; D011658:Pulmonary Fibrosis / Q000150:complications / Q000503:physiopathology; D012129:Respiratory Function Tests; D018570:Risk Assessment; D012720:Severity of Illness Index; D012907:Smoking / Q000009:adverse effects*
D016207:Cytokines; D004785:Environmental Pollutants